JAZZ Jazz Pharmaceuticals
- 112.050
- +5.730+5.39%
- 111.950
- -0.100-0.09%
Jazz Pharmaceuticals News
Jazz Pharmaceuticals Analyst Ratings
Goldman Sachs Initiates Coverage On Jazz Pharmaceuticals With Buy Rating, Announces Price Target of $169
HC Wainwright & Co. Reiterates Buy on Jazz Pharmaceuticals, Maintains $200 Price Target
UBS Adjusts Price Target on Jazz Pharmaceuticals to $117 From $121, Maintains Neutral Rating
Jazz Pharmaceuticals Analyst Ratings
Barclays: Maintaining the Jazz Pharmaceuticals (JAZZ.US) rating, adjusted from an increase in holdings to an increase rating, and the target price was adjusted from $230.00 to $200.00.
Analysts Offer Insights on Healthcare Companies: Kronos Bio (KRON), Jazz Pharmaceuticals (JAZZ) and KalVista Pharmaceuticals (KALV)
RBC Capital Reaffirms Their Buy Rating on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals Analyst Ratings
Buy Rating Affirmed: Jazz Pharmaceuticals' Resilient Base and Promising Pipeline Drive Positive Outlook
Barclays Remains a Buy on Jazz Pharmaceuticals (JAZZ)
Jazz Pharmaceuticals (JAZZ) Gets a Buy From Barclays
Cantor Fitzgerald: Reiterated the Jazz Pharmaceuticals (JAZZ.US) rating and adjusted from an increase in holdings to an increase in holdings rating, with a target price of $180.00.
Jazz Pharmaceuticals Analyst Ratings
Analysts' Opinions Are Mixed on These Healthcare Stocks: Bluebird Bio (BLUE), Sarepta Therapeutics (SRPT) and Jazz Pharmaceuticals (JAZZ)
JPMorgan Raises Jazz Pharmaceuticals' Price Target to $190 From $170, Maintains Overweight Rating
Jazz Pharmaceuticals Analyst Ratings
Cantor Fitzgerald Reiterates Overweight on Jazz Pharmaceuticals, Maintains $180 Price Target
Optimistic Outlook on Jazz Pharmaceuticals' Zanidatamab Across Multiple Cancer Types: A Buy Rating Analysis
Piper Sandler Maintains Overweight on Jazz Pharmaceuticals, Raises Price Target to $188
Analysis
Price Target
No Data
